Gaithersburg, Maryland-based Novavax has signed a three-year agreement with the Bill & Melinda Gates Medical Research Institute to make its vaccine adjuvant available for use in pre-clinical vaccine research.
Its Matrix-M adjuvant is the basis for its protein-based COVID-19 vaccine, and is being used in development of new influenza and combination influenza-COVID vaccines. An adjuvant is an ingredient in some vaccines to help create a stronger immune response.
Novavax recently reported positive results in Phase 2 human trials for the combination vaccine.
“We are excited to partner with the Bill & Melinda Gates Medical Research Institute to include our unique technology in their public health-focused vaccine research efforts,” said Novavax chief executive John Jacobs.
“Our Matrix-M adjuvant is proven to enhance and broaden the immune system response when included in vaccines and is already a key component of COVID and malaria vaccines on the market today.”
Last month, Novavax announced cost-cutting plans to reduce expenses by 40% to 50% this year, including cutting about 20% of its global workforce, or about 400 jobs.
In February, Novavax secured a new deal to sell the U.S. government another 1.5 million doses of its protein-based COVID vaccine, ahead of vaccine privatization later this year.
Novavax began developing its COVID vaccine in 2020 with government funding, but the vaccine did not received final emergency-use approval until July 2022.
The Bill & Melinda Gates Medical Research Institute is an affiliate of the Bill & Melinda Gates Foundation, and is currently focused on programs addressing global diseases such as TB, malaria, diarrheal, and maternal, newborn and child illnesses.
Get breaking news and daily headlines delivered to your email inbox by signing up here.
© 2023 WTOP. All Rights Reserved. This website is not intended for users located within the European Economic Area.